Comprehensive Study Guide to T-Cell Recognition, MHC Genetics and Processing, and Lymphocyte Development

Functional Foundations of Adaptive Immunity and the Cellular Need for T Cells

• Innate vs. Adaptive Immune Kinetics:

  • Innate Immunity: Provides immediate host defense within $0\text{--}12\,\text{hours}$ of pathogen exposure through pre-existing barriers (epithelial layers), soluble factors (complement cascade), and rapid effector cells (phagocytes, Natural Killer [NK] cells).
  • Adaptive Immunity: Operates with delayed kinetics ($1\text{--}7\,\text{days}$ following initial exposure), characterized by antigen-specific clonal expansion, receptor diversification, and memory generation by B and T lymphocytes.

• Fundamental Distinction in Antigen Recognition Between Lymphocyte Classes:

  • B-Cell Recognition: Recognizes intact, native macromolecular structures (soluble proteins, polysaccharides, lipids, toxins, and cell-surface determinants) via the membrane-bound B-cell receptor (BCR) or secretable immunoglobulins.
  • T-Cell Recognition: Recognizes almost exclusively small, linear peptide fragments ($8\text{--}25\,\text{amino acids}$) held in specialized peptide-binding grooves of Major Histocompatibility Complex (MHC) molecules presented on the surfaces of host cells.

• Pathogen Evasion Strategies Demanding Cell-Mediated Immunity:

  • Surface Antigenic Alterations: Pathogens evade humoral immunity via antigenic drift (minor point mutations altering surface epitopes) and antigenic shift (reassortment of genomic segments generating novel viral strains). While antibodies fail when surface determinants mutate, T cells detect conserved internal viral peptides processed and presented on MHC molecules.
  • Intracellular Pathogen Sequestration: Strictly humoral responses cannot reach microbes sequestered within intracellular niches. An example is Listeria monocytogenes (etiologic agent of listeriosis associated with contaminated deli meats and unpasteurized cheeses, causing $\sim 1{,}600\,\text{cases}$ and $260\,\text{deaths}$ annually in the US among pregnant women, neonates, elderly, and immunocompromised individuals). Following phagocytosis, L. monocytogenes lyses the phagolysosome, escapes into the host cytosol, replicates, and polymerizes host actin filaments ("actin-based locomotion") to form filopod projections that invade adjacent cells without ever encountering extracellular antibodies.
  • Allograft Recognition: As established by Sir Peter Medawar in the 1960s using murine skin graft exchanges between inbred strains, allograft rejection is mediated by cellular immune responses where recipient T cells recognize foreign polymorphic MHC alloantigens either directly on donor dendritic cells or indirectly via recipient dendritic cells presenting processed donor alloantigens.

Architecture, Genetics, and Diversity Generation of the T-Cell Receptor

• Structural Features of the T-Cell Receptor (TCR):
  • The conventional TCR is a membrane-bound, disulfide-linked heterodimer composed of an alpha ($\alpha$) and a beta ($\beta$) chain (or an alternative gamma-delta [$\gamma:\delta$] pair).
  • Unlike immunoglobulins, the TCR is strictly membrane-tethered, is never secreted, and possesses only a single monomeric antigen-binding site per heterodimer.
  • Each chain consists of an amino-terminal variable ($V$) domain, a constant ($C$) domain, a hydrophobic transmembrane region, and a short cytoplasmic tail lacking intrinsic catalytic or signaling activity.
  • The antigen-binding site is formed by three hypervariable complementary-determining regions (CDR1, CDR2, and CDR3) per chain. CDR1 and CDR2 primarily make contact with the conserved helices of the host MHC molecule, while CDR3—encoded across the $V(D)J$ junction—directly contacts the bound foreign peptide.

• Comparative Analysis of Antigen Receptors (BCR vs. TCR):

  • Gene Segments: Both utilize $V$, $D$, and $J$ segments ($\text{H}$ chain and TCR $\beta$) or $V$ and $J$ segments ($\text{L}$ chain and TCR $\alpha$).
  • Somatic Recombination: Both require $V(D)J$ rearrangement catalyzed by RAG-1/RAG-2.
  • Allelic Exclusion: Strictly enforced in both lineages to guarantee that each lymphocyte expresses a receptor of single specificity.
  • Somatic Hypermutation: Operates robustly in activated B cells to drive affinity maturation; strictly absent in T cells to preserve thymic self-tolerance and prevent auto-reactivity in the periphery.
  • Secreted Isoforms: Present in B cells (antibodies); absent in T cells.
  • Isotype Switching: Present in B cells ($\text{IgM} \rightarrow \text{IgG, IgA, IgE}$); absent in T cells.
  • Valency: BCR possesses two identical binding sites (divalent); TCR possesses one binding site (monovalent).

• Genomic Organization of TCR Loci:

  • TCR $\alpha$-chain Locus: Located on human chromosome 14; contains $70\text{--}80\,V_\alpha$ gene segments and $61\,J_\alpha$ gene segments preceding a single $C_\alpha$ gene. Notably, the entire TCR $\delta$-chain locus is embedded internally between the $V_\alpha$ and $J_\alpha$ segments.
  • TCR $\beta$-chain Locus: Located on human chromosome 7; organized into two tandem cassettes, each comprising one $D_\beta$ segment, $6\text{--}7\,J_\beta$ segments, and a single $C_\beta$ gene ($D_{\beta 1}\text{--}J_{\beta 1}\text{--}C_{\beta 1}$ and $D_{\beta 2}\text{--}J_{\beta 2}\text{--}C_{\beta 2}$), positioned downstream of $52\,V_\beta$ gene segments.

• Enzymatic Machinery of $V(D)J$ Recombination:

  • Recombination signal sequences (RSS) flank each gene segment, consisting of a conserved heptamer and nonamer separated by a non-conserved spacer of either $12\,\text{bp}$ or $23\,\text{bp}$. The "$12/23\,\text{rule}$" ensures that segments flanked by a $12\,\text{bp}$ spacer recombine exclusively with segments flanked by a $23\,\text{bp}$ spacer.
  • RAG-1 and RAG-2: Lymphoid-specific endonuclease complex that binds the RSS, introduces single-strand nicks at the coding-signal junctions, and mediates transesterification to form hairpin loops at the coding ends and blunt signal ends.
  • Non-Homologous End Joining (NHEJ) Machinery: Ubiquitous double-strand break repair proteins resolve the breaks:
    • Ku70:Ku80 Heterodimer: Binds to DNA ends and recruits the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs).
    • Artemis: Endonuclease phosphorylated by DNA-PKcs; cleaves the DNA hairpins asymmetrically to generate palindromic P-nucleotides.
    • Terminal Deoxynucleotidyl Transferase (TdT): Adds template-independent N-nucleotides to the cleaved coding ends, drastically expanding junctional diversity.
    • XRCC4 and DNA Ligase IV: Seal the final coding joint and signal joint. Excised intervening DNA circles (T-cell receptor excision circles, or TRECs) persist non-replicatively, serving as clinical diagnostic markers for recent thymic emigrants.

• Quantitative Metrics of Repertoire Diversity:

• The CD3 Complex and Signal Transduction:

  • Because the cytoplasmic tails of the $\alpha:\beta$ heterodimer comprise only $3\text{--}4\,\text{amino acids}$, cell-surface transport and signaling require association in the endoplasmic reticulum with the invariant CD3 complex.
  • The complex comprises three dimers: $\text{CD3}\gamma\epsilon$, $\text{CD3}\delta\epsilon$, and a $\zeta\zeta$ homodimer (zeta chains). These chains possess Immunoreceptor Tyrosine-based Activation Motifs (ITAMs).
  • Signaling Cascade: Ligation of the TCR by a cognate peptide:MHC complex recruits the co-receptor-associated tyrosine kinase Lck, which phosphorylates ITAM tyrosines. Doubly phosphorylated ITAMs recruit ZAP-70 via its tandem SH2 domains. Activated ZAP-70 phosphorylates scaffold proteins, leading to downstream activation of:
    • PLC$\gamma$: Mediates PIP2 cleavage into IP3 (releasing intracellular $\text{Ca}^{2+}$ flux and activating calcineurin/NFAT) and DAG (activating PKC$\theta$/NF-$\kappa$B).
    • Ras/MAPK Pathway: Drives ERK activation and subsequent AP-1 assembly.
    • Rac/JNK and p38 Pathways: Mediate cytoskeletal reorganizations and transcription factor activation.
    • PI3K/Akt Pathway: Regulates cell survival, cellular metabolism, and translational initiation.

• Clinical Correlate — Severe Combined Immunodeficiency (SCID):

  • Caused by genetic defects in $V(D)J$ recombination (autosomal recessive RAG1 or RAG2 mutations resulting in complete absence of B and T cells; partial activity causes Omenn syndrome; Artemis defects cause radiosensitive SCID).
  • Classic Presentation: Severe failure to thrive, early-onset recurrent diarrhea, chronic candidiasis (thrush), and persistent otitis media starting at $4\,\text{weeks}$ of age.
  • Laboratory Diagnostic Findings: Normal neutrophil counts ($2600\,\text{cells}/\mu\text{L}$; reference $2000\text{--}7500\,\text{cells}/\mu\text{L}$), profound lymphopenia with T cells constituting only $2\%$ of peripheral lymphocytes (reference $60\text{--}80\%$) and B cells $<1\%$ (reference $15\text{--}25\%$).
  • Historical Paradigm: David Vetter (1971–1984), who lived in a sterile isolation bubble until succumbed following an unmatched bone marrow transplant that inadvertently transmitted Epstein-Barr virus (EBV).

Major Histocompatibility Complex: Architecture, Processing, and Presentation

• Structural Comparison of MHC Class I and Class II:
  • MHC Class I: Composed of a polymorphic transmembrane heavy chain ($\alpha_1, \alpha_2, \alpha_3$ domains) non-covalently complexed with the invariant, non-polymorphic $\beta_2\text{-microglobulin}$ ($\beta_2\text{m}$) encoded on chromosome 15. The peptide-binding groove is closed at both ends, formed by the $\alpha_1$ and $\alpha_2$ helices above an eight-strand $\beta$-pleated sheet, accommodating short nonamers or decamers ($8\text{--}10\,\text{amino acids}$).
  • MHC Class II: Composed of two polymorphic transmembrane chains ($\alpha_1, \alpha_2$ and $\beta_1, \beta_2$). The peptide-binding groove is open at both ends, formed by the interaction of $\alpha_1$ and $\beta_1$ domains, accommodating longer, variable peptides ($13\text{--}25\,\text{amino acids}$) that extend beyond the cleft.

• Co-Receptor Specificities:

  • CD8 (Cytotoxic T Cells): An $\alpha\beta$ heterodimer (or $\alpha\alpha$ homodimer) that binds directly to the non-polymorphic $\alpha_3$ domain of MHC class I molecules.
  • CD4 (Helper T Cells): A monomeric four-domain immunoglobulin-like molecule ($D_1\text{--}D_4$) that binds specifically to the non-polymorphic $\beta_2$ domain of MHC class II molecules.

• Comparative Processing and Presentation Pathways:

• MHC Class I Endogenous Processing Pathway:
  • Ubiquitination and Proteasomal Cleavage: Defective ribosomal products (DRiPs) and cytosolic proteins are polyubiquitinated via an E1-E2-E3 ubiquitin ligase cascade (requiring an invariant chain of at least 4 ubiquitins linked via Lys48) and funneled into the 26S proteasome (comprising a 20S catalytic cylinder capped by two 19S regulatory complexes).
  • Immunoproteasome: Under the influence of interferon-gamma (IFN-$\gamma$), the constitutive catalytic subunits $\beta_1$, $\beta_2$, and $\beta_5$ are replaced by $\beta_{1i}$ (LMP2), $\beta_{2i}$ (MECL-1), and $\beta_{5i}$ (LMP7), and the 19S cap is swapped for the PA28 proteasome activator cap. This shifts cleavage specificity toward hydrophobic or basic carboxyl-terminal residues ideal for MHC class I anchoring and TAP transport.
  • TAP Translocation: The Transporter associated with Antigen Processing (a heterodimer of TAP1 and TAP2 in the ER membrane) hydrolyzes ATP to translocate peptides of $8\text{--}16\,\text{amino acids}$ into the ER lumen.
  • The Peptide-Loading Complex (PLC):
    1. Newly synthesized MHC class I heavy chains bind the membrane-bound chaperone calnexin until $\beta_2\text{m}$ binds.
    2. Upon $\beta_2\text{m}$ binding, calnexin dissociates, and the heterodimer enters the PLC, composed of calreticulin, the thiol oxidoreductase ERp57, tapasin, and TAP.
    3. Tapasin bridges the MHC class I molecule to TAP and physically widens the peptide-binding cleft to perform peptide editing, selecting only high-affinity peptides.
  • ERAP Trimming: Peptides that bind with amino-terminal extensions are trimmed in the ER lumen by Endoplasmic Reticulum Aminopeptidase (ERAP) down to nonamers ($9\,\text{amino acids}$).
  • Export: High-affinity peptide binding stabilizes the MHC class I molecule, causing dissociation from the PLC and transport via coatomer-coated vesicles through the Golgi network to the plasma membrane.

• MHC Class II Exogenous Processing Pathway:
  • Antigen Uptake: Antigens enter professional antigen-presenting cells via receptor-mediated endocytosis (surface Ig on B cells, mannose/scavenger receptors on macrophages), macropinocytosis (bulk fluid uptake by dendritic cells), or phagocytosis (particulates and apoptotic bodies).
  • Acidification and Proteolysis: Endosomes fuse with lysosomes, undergoing progressive acidification ($\text{pH} 7.0 \rightarrow 6.0 \rightarrow 4.5$ via vacuolar $\text{H}^+\text{-ATPases}$), which activates acid proteases, primarily the cathepsins (Cathepsins B, D, S, and L) and Gamma-Interferon-inducible Lysosomal Thiol Reductase (GILT), reducing disulfide bonds and cleaving antigens into fragments.
  • Invariant Chain (Ii) Guidance: In the ER lumen, three newly synthesized MHC class II $\alpha\beta$ heterodimers assemble around an invariant chain (Ii, CD74) trimer. A flexible segment of Ii, termed the Class II-associated Invariant Chain Peptide (CLIP), lies directly within the peptide-binding groove, preventing premature binding of ER-resident polypeptides.
  • Targeting to the MIIC: The cytoplasmic tail of Ii contains dileucine-based sorting signals directing the nonameric complex from the trans-Golgi into endosomal compartments (the MHC Class II compartment, or MIIC).
  • CLIP Cleavage and Peptide Exchange: Within the MIIC, endosomal proteases (principally Cathepsin S in dendritic cells and B cells; Cathepsin L in thymic cortical epithelium) cleave Ii in stages, leaving only the short CLIP fragment in the groove.
  • HLA-DM and HLA-DO Regulation: The non-classical, non-polymorphic chaperone HLA-DM binds to the $\alpha$ chain of MHC class II, stabilizing an open conformation that induces the release of CLIP and facilitates high-affinity peptide binding (peptide editing). HLA-DO, expressed predominantly in B cells and the thymus, functions as a negative regulator that binds HLA-DM and dampens peptide exchange until acidified late endosomes are reached.

• Cross-Presentation and Autophagy:

  • Cross-Presentation: Classical dendritic cells internalize exogenous antigens (from viral infections restricted to parenchymal cells such as Hepatitis C virus in hepatocytes or Influenza in respiratory epithelium) and route them into the MHC class I cytosolic pathway to prime naive $\text{CD8}^+$ T cells. Antigens escape endocytic vesicles into the cytosol, undergo degradation by the immunoproteasome, are transported into the ER by TAP (or retro-transported into phagolysosomal vesicles), and load onto MHC class I.
  • Autophagy: Host cells continuously capture cytoplasmic proteins, damaged organelles, and cytosolic viruses (e.g., Herpes Simplex Virus) within double-membrane autophagosomes that fuse with lysosomes, delivering endogenous antigens into the MHC class II processing pathway to maintain self-tolerance or stimulate $\text{CD4}^+$ T cells.

• Cellular Distribution of MHC Expression:

  • MHC Class I: Expressed on virtually all nucleated cells, reflecting susceptibility to intracellular viral infection. Erythrocytes lack MHC class I entirely. Non-hematopoietic tissues (liver hepatocytes, kidney epithelium, brain parenchyma) express low baseline levels that markedly upregulate during inflammation.
  • MHC Class II: Strictly restricted to professional antigen-presenting cells:
    • Dendritic Cells (DCs): Constitutively express high levels of MHC class II and co-stimulatory molecules (CD80/B7-1, CD86/B7-2); primary activators of naive T cells.
    • B Cells: Constitutively express MHC class II; internalize soluble antigens with high affinity via surface immunoglobulin; express B7 upon activation.
    • Macrophages: Express moderate baseline MHC class II and low B7, both massively upregulated upon phagocytosis of pathogens and IFN-$\gamma$ stimulation.
    • Atypical APCs: Mast cells, basophils, eosinophils, and type 3 innate lymphoid cells (ILC3s) show inducible MHC class II expression under specific cytokine milieus (e.g., type 2 immune responses) but generally lack robust capacity to prime naive $\text{CD4}^+$ T cells.

Genetics, Polymorphism, and Clinical Correlates of the MHC

• Chromosomal Organization (Human Chromosome 6):
  • The Human Leukocyte Antigen (HLA) complex spans over 4 megabases on the short arm of chromosome 6 ($6\text{p}21.3$), divided into three contiguous regions:
    • Class II Region (Centromeric): Encodes HLA-DP ($\text{DPA1, DPB1}$), HLA-DQ ($\text{DQA1, DQB1}$), HLA-DR ($\text{DRA, DRB1, DRB3, DRB4, DRB5}$), non-classical peptide-exchange chaperones HLA-DM ($\text{DMA, DMB}$) and HLA-DO ($\text{DOA, DOB}$), as well as antigen processing components: TAP1, TAP2, LMP2 ($\beta_{1i}$), LMP7 ($\beta_{5i}$), and tapasin.
    • Class III Region (Central): Encodes non-MHC immune mediators including complement components ($\text{C2, C4A, C4B}$, Factor B) and tumor necrosis factors ($\text{TNF}-\alpha, \text{LT}-\alpha, \text{LT}-\beta$).
    • Class I Region (Telomeric): Encodes the classical heavy chains HLA-A, HLA-B, and HLA-C, alongside non-classical molecules HLA-E, HLA-F, and HLA-G.

• Transcriptional Regulation and Bare Lymphocyte Syndrome (BLS):

  • Expression of all MHC class II genes is coordinately governed by the MHC Class II Transactivator (CIITA), a master non-DNA-binding coactivator that docks onto an enhanceosome nucleated by DNA-binding complexes:
    • RFX Complex: Composed of RFX5, RFX-AP, and RFX-ANK, binding the conserved X1 box.
    • X2BP / CREB: Binds the X2 box.
    • NF-Y: Binds the conserved Y box.
  • Clinical Case — Bare Lymphocyte Syndrome Type II: A 6-month-old infant presenting with tachypnea, hypoxemia, recurrent viral bronchiolitis, and secondary bacterial pneumonia. Despite normal B and NK cell counts, laboratory evaluation shows an almost complete absence of peripheral $\text{CD4}^+$ T cells, normal IgM, undetectable IgG and IgA, and absent antibody titers following tetanus and diphtheria vaccinations. Genetic etiology involves mutations in CIITA or the RFX subunits, silencing class II transcription and precluding positive thymic selection of $\text{CD4}^+$ T cells.
  • Bare Lymphocyte Syndrome Type I: Caused by loss-of-function mutations in TAP1 or TAP2, characterized by $<1\%$ of normal surface MHC class I expression and severe deficiencies in $\text{CD8}^+$ T cells.

• Genetic Principles Governing MHC:

  • Polygeny: The existence of multiple, distinct classical MHC class I (HLA-A, -B, -C) and class II (HLA-DP, -DQ, -DR) structural genes within every individual genome.
  • Polymorphism: The presence of hundreds to thousands of alternative allelic variants of each locus within the human population. The MHC is the most polymorphic gene cluster known in vertebrates.
  • Haplotype and Codominance: An MHC haplotype is the set of linked alleles located on a single chromosome 6. Because maternal and paternal chromosomes are expressed codominantly without allelic exclusion, a typical heterozygous individual simultaneously expresses six distinct MHC class I molecules (three from each parent) and up to eight distinct MHC class II molecules (due to combinatorial pairing of maternal and paternal $\alpha$ and $\beta$ chains at the DP and DQ loci, alongside extra DRB chains).

• Nomenclature of HLA Alleles:

  • Illustrated by HLA-DRB1*0301:
    • HLA: Human Leukocyte Antigen complex.
    • DRB1: Specific genetic locus and protein chain (HLA-DR $\beta_1$ chain).
    • *: Separator between gene locus and specific allele designation.
    • 03: Allele family, historically defined by serological typing.
    • 01: Specific allotypic variant possessing unique nucleotide and amino acid substitutions.

• Mechanism and Impact of Allelic Polymorphism:

  • Amino acid differences across allotypes are not distributed randomly; they cluster almost exclusively within the $\alpha_1$ and $\alpha_2$ domains of MHC class I and the $\alpha_1$ and $\beta_1$ domains of MHC class II, specifically lining the peptide-binding groove.
  • These substitutions alter the configuration, depth, and charge of the anchor pockets, governing the sequence motif of anchor residues that a given MHC molecule can bind (e.g., MHC class I typically requires specific hydrophobic or basic residues at position 2 and the carboxyl-terminal position 9).

• MHC Restriction:

  • A TCR does not recognize foreign peptide alone or MHC alone; it recognizes the combined structural face created by the peptide nested within a self-MHC molecule. A TCR specific for peptide $X$ bound to $\text{MHC}^a$ will fail to recognize peptide $X$ bound to an allogeneic $\text{MHC}^b$, or an unrelated peptide $Y$ bound to $\text{MHC}^a$.

• Generation of Novel Alleles:

  • New alleles evolve via natural selection driven by infectious pressures through:
    • Interallelic Conversion: Recombination between two alleles of the same locus (e.g., exchanging sequences between $B*51:01$ and $B*35:01$ to produce $B*53:01$).
    • Gene Conversion: Recombination between alleles of adjacent homologous loci (e.g., looping between $B*15:01$ and $Cw*01:02$ to generate the hybrid allele $B*46:01$).

• Clinical HLA-Disease Associations:

  • Relative Risk Formula:$\text{RR} = \frac{(\text{Ag}^+/\text{Ag}^-)_{\text{disease}}}{(\text{Ag}^+/\text{Ag}^-)_{\text{control}}}$

• HIV Disease Progression: Individuals heterozygous at all three classical HLA class I loci (HLA-A, -B, -C) maintain significantly longer AIDS-free survival times following seroconversion compared to individuals who are homozygous at one or more loci, directly reflecting broader peptide presentation breadth against viral escape mutants.

Superantigens and Atypical Immune Activation

• Mechanism of Superantigen Action:

  • Superantigens are intact, unprocessed bacterial or viral toxins that bypass classical intracellular antigen processing.
  • They cross-link the outer face of an MHC class II molecule with specific variable segments ($V_\beta$) of the T-cell receptor outside the canonical antigen-binding cleft.
  • Consequence: Instead of activating a single antigen-specific clone ($1\,\text{in } 10^5\text{--}10^6\,\text{T cells}$), a superantigen polyclonally activates $2\text{--}20\%$ of the entire peripheral T-cell repertoire, causing massive release of systemic pro-inflammatory cytokines ($\text{IL}-1, \text{IL}-2, \text{TNF}-\alpha, \text{IFN}-\gamma$), precipitating capillary leakage, hemodynamic collapse, toxic shock syndrome, and subsequent profound deletion or anergy of responsive T cells.
  • Canonical Examples: Staphylococcal enterotoxins (SE), Toxic Shock Syndrome Toxin-1 (TSST-1) from Staphylococcus aureus, and streptococcal pyrogenic exotoxins.

• Kawasaki Disease:

  • An acute, systemic necrotizing vasculitis of unknown etiology predominantly affecting infants and children under 5 years of age ($<20{,}000\,\text{US cases annually}$).
  • Clinical Diagnostic Criteria: High-spiking fever lasting $>5\,\text{days}$, bilateral non-exudative conjunctivitis, strawberry tongue, erythema and edema of hands and feet followed by periungual desquamation, polymorphous truncal exanthem, and unilateral cervical lymphadenopathy. Presumed to involve superantigenic immune triggering, with severe risk of coronary artery aneurysms if untreated.

Unconventional T Cells: Gamma-Delta (γ:δ) T-Cell Biology

• General Characteristics of $\gamma:\delta$ T Cells:

  • Account for only $\sim 2\%$ of total circulating peripheral T cells, but represent major intraepithelial lymphocyte subsets in mucosal and barrier tissues (gut, skin, reproductive tract).
  • Function at the interface of innate and adaptive immunity, recognizing stress-induced non-peptide antigens directly without requirement for classical MHC restriction or professional antigen processing.

• Tissue-Specific Distribution and V-Gene Usage:

• Antigen Specificities and Presentation Mechanisms:
  • $V_\gamma 9:V_\delta 2$ T Cells (Blood): Constitute $50\text{--}95\%$ of circulating $\gamma:\delta$ T cells. Recognize small, non-peptidic phosphoantigens derived from microbial isoprenoid synthesis or dysregulated host mevalonate pathways:
    • Microbial: Hydroxymethyl-but-2-enyl pyrophosphate (HMBPP), synthesized by bacteria (Mycobacterium tuberculosis) and apicomplexan parasites (Plasmodium).
    • Host Self-Antigen: Isopentenyl pyrophosphate (IPP), overproduced by malignant or intracellularly stressed cells.
    • Synthetic Activators: Zoledronate (aminobisphosphonate) and Bromohydrin pyrophosphate.
    • Receptor Mechanism: Phosphoantigens bind the intracellular B30.2 domain of the transmembrane protein butyrophilin 3A1 (BTN3A1). This induces a conformational change recruiting butyrophilin 2A1 (BTN2A1), which directly cross-links and triggers the $V_\gamma 9:V_\delta 2$ TCR.
  • $V_\delta 4:V_\gamma 5$ T Cells: Recognize the Endothelial Protein C Receptor (EPCR) on cytomegalovirus (CMV)-infected cells and endothelial tumors. EPCR possesses an MHC class I-like fold that binds host phospholipids.
  • $V_\gamma:V_\delta 1$ T Cells (Mucosal Epithelium): Recognize lipid and glycolipid antigens presented by CD1d (a non-classical MHC class I-like molecule associated with $\beta_2\text{m}$), including sulfatide (a major glycosphingolipid), mycobacterial mycolic acid, and marine sponge-derived $\alpha$-galactosylceramide ($\alpha\text{-GalCer}$).

Stages of B-Lymphocyte Development in the Bone Marrow

• Six Functional Phases of the B-Cell Life Cycle:
  1. Repertoire Assembly: Somatic gene rearrangement generating diverse, clonally distributed BCRs in the bone marrow.
  2. Negative Selection: Deletion, editing, or anergy of self-reactive immature B cells binding bone marrow self-antigens.
  3. Positive Selection: Immature B cells accessing secondary lymphoid follicles receive survival and maturation signals.
  4. Searching for Infection: Recirculation of mature naive B cells through blood, lymph, and secondary lymphoid organs.
  5. Finding Infection: Clonal selection and activation by foreign antigens in secondary lymphoid tissues.
  6. Attacking Infection: Clonal expansion, somatic hypermutation, affinity maturation, class-switch recombination, and differentiation into antibody-secreting plasma cells and quiescent memory B cells.

• Stages, Phenotypes, and Transcription Factors:

  • Hematopoietic Stem Cell (HSC): Surface phenotype $\text{CD34}^+$.
  • Common Lymphoid Progenitor (CLP): Surface phenotype $\text{CD34}^+, \text{CD10}^+$.
  • B-Cell Precursor: Surface phenotype $\text{CD34}^+, \text{CD10}^+, \text{CD127}^+$ (IL-7 receptor $\alpha$ chain).
  • Pro-B Cell: Surface phenotype $\text{CD34}^+, \text{CD10}^+, \text{CD127}^+, \text{CD19}^+$.
  • Bone Marrow Stromal Interactions: Developing progenitors adhere to stromal cells via Cell Adhesion Molecules (CAMs) and integrin VLA-4 binding to stromal VCAM-1. The receptor tyrosine kinase Kit (CD117) on pro-B cells binds stromal Stem Cell Factor (SCF), initiating proliferation. Progenitors subsequently express the IL-7 receptor and proliferate in response to stromal-secreted IL-7.
  • Transcriptional Drivers: E2A and Early B-cell Factor (EBF) direct commitment to the B-cell lineage by inducing expression of Pax-5 (the master B-cell lineage commitment factor). Pax-5 represses non-B-lineage genes while opening the immunoglobulin heavy-chain chromatin locus.

• Sequential Immunoglobulin Gene Rearrangement:

• Heavy-Chain Rearrangement Checkpoint and the Pre-BCR:
  • During the early pro-B stage, $D_H$ to $J_H$ rearrangement occurs on both chromosomes simultaneously. Late pro-B cells attempt $V_H$ to $DJ_H$ rearrangement on the first chromosome. Because non-homologous joining causes frameshifts, each rearrangement has only a $1\text{ in } 3$ ($\sim 33\%$) chance of being in-frame, resulting in an estimated $66\%$ initial failure rate. If nonproductive, the second chromosome rearranges. If both fail, the cell undergoes apoptosis ($\sim 45\text{--}50\%$ of pro-B cells die at this checkpoint).
  • Successful in-frame rearrangement results in synthesis of the $\mu$ heavy chain, which pairs with a surrogate light chain composed of $\lambda 5$ and VpreB alongside signaling chains $\text{Ig}\alpha$ (CD79a) and $\text{Ig}\beta$ (CD79b) to assemble the Pre-B-Cell Receptor (Pre-BCR).
  • Pre-BCR Signaling Consequences:
    1. Halts heavy-chain gene rearrangement by downregulating RAG-1 and RAG-2 and directing chromatin condensation at the second heavy-chain allele, enforcing allelic exclusion.
    2. Drives $5\text{--}6\,\text{rounds}$ of clonal expansion in large pre-B cells, expanding a single productive heavy-chain clone into $\sim 100\,\text{small pre-B cells}$.
    3. Signals exit from the cell cycle and re-expression of RAG-1 and RAG-2 to initiate light-chain gene rearrangement.

• Light-Chain Rearrangement Checkpoint:

  • Light-chain rearrangement initiates at the $\kappa$ locus on the first chromosome. If nonproductive, successive rearrangements occur on the same chromosome utilizing upstream $V_\kappa$ and downstream $J_\kappa$ segments. If the first $\kappa$ locus is exhausted nonproductively, rearrangements proceed to the second $\kappa$ allele, followed sequentially by the first and second $\lambda$ alleles. Due to multiple rescue opportunities, $\sim 85\%$ of pre-B cells successfully produce a functional light chain.
  • Upon assembly of a complete monomeric IgM molecule ($\mu$ heavy chain complexed with a $\kappa$ or $\lambda$ chain) with $\text{Ig}\alpha/\text{Ig}\beta$, further rearrangement ceases, and the cell emerges as an immature B cell.

• Clinical Correlate — X-Linked Agammaglobulinemia (XLA):

  • A hereditary immunodeficiency caused by mutations in Bruton's Tyrosine Kinase (Btk), an essential downstream component of Pre-BCR signaling that activates phospholipase C-gamma ($\text{PLC}\gamma$).
  • In the absence of functional Btk, pre-B cells fail to receive survival and expansion signals, arresting development between the pre-B and immature B-cell stages.
  • Clinical Vignette: A 9-year-old boy presents with chronic cough and right middle lobe atelectasis. Medical history reveals recurrent childhood episodes of otitis media, bacterial pneumonia, and erysipelas. Flow cytometry confirms the complete absence of circulating $\text{CD19}^+$ B cells ($0.03\%$ vs. control $5.2\%$) alongside profound hypogammaglobulinemia (serum IgG $80\,\text{mg/dL}$; reference range $600\text{--}1500\,\text{mg/dL}$; undetectable IgM and IgA), while $\text{CD3}^+$ T-cell counts and proliferative responses are normal. Treatment requires lifelong intravenous immunoglobulin (IVIG) therapy.

B-Cell Selection, Central Tolerance, and Receptor Editing

• Central Tolerance in the Bone Marrow:

  • Because $V(D)J$ recombination operates randomly, approximately $75\%$ of generated immature B cells exhibit high affinity for multivalent or soluble self-antigens.
  • Fate 1 — Multivalent Self-Antigen Binding (Receptor Editing): Strong cross-linking of surface IgM by multivalent membrane antigens on bone marrow stromal cells halts development and retains the immature B cell in the bone marrow. The cell maintains expression of RAG-1, RAG-2, and TdT, selectively opening the light-chain loci for receptor editing.
    • Upstream $V_\kappa$ and downstream $J_\kappa$ segments recombine, excising the autoreactive $V_\kappa J_\kappa$ joint.
    • If the new light chain is non-self-reactive, the B cell downregulates RAG and exits the marrow.
    • If all light-chain alleles ($\kappa$ and $\lambda$) are exhausted without eliminating autoreactivity, the cell undergoes clonal deletion via apoptosis.
  • Fate 2 — Soluble Monovalent Self-Antigen Binding (Anergy): Binding to low-affinity, soluble univalent self-antigens delivers weak, non-cross-linking signals that drive the B cell into a state of developmental arrest known as anergy. Anergic B cells downregulate surface IgM, express normal to elevated levels of surface IgD ($\text{IgM}^{\text{low}}\text{IgD}^{\text{high}}$), and enter peripheral circulation, but are competitively excluded from lymphoid follicles and die within $1\text{--}5\,\text{days}$.
  • Fate 3 — No Self-Antigen Binding (Survival): Immature B cells that exhibit no reactivity to self-components mature normally, express alternative mRNA splicing of the heavy chain transcript to produce surface IgM and IgD ($\mu^+ \delta^+$), and emigrate via sinusoidal vessels into the peripheral blood.

• Peripheral Tolerance:

  • Autoreactive B cells encountering tissue-restricted antigens not represented in the bone marrow stroma cannot undergo receptor editing in the periphery. They are controlled strictly via clonal deletion (apoptosis), anergy, or immunological ignorance (antigen sequestered behind anatomical barriers or present at concentrations below the threshold of activation without T-cell help).

B-Cell Homing, Maturation, and Germinal Center Dynamics

• Recirculation and Lymph Node Architecture:
  • Approximately $30\,\text{billion}$ immature B cells exit the bone marrow daily, comprising $5\text{--}10\%$ of the total peripheral pool. In the absence of positive selection, $50\%$ of peripheral immature B cells die every $3\,\text{days}$.
  • Circulating B cells extravasate across the walls of High Endothelial Venules (HEVs) into the paracortex of lymph nodes, guided by a chemokine gradient of CCL21 (produced by stromal cells and dendritic cells) and CCL19 (produced by dendritic cells) binding to the receptor CCR7 on B cells.

• Follicular Entry and Final Maturation:

  • From the paracortex, B cells migrate into primary lymphoid follicles attracted by the chemokine CXCL13, produced constitutively by Follicular Dendritic Cells (FDCs), which binds to CXCR5 on B cells.
  • Within the follicle, physical contact between immature transitional B cells and FDCs provides critical survival signals:
    • Lymphotoxin (LT): Expressed as a membrane heterotrimer ($\text{LT}-\alpha_1\beta_2$) on B cells, binds to LT receptors on FDCs, maintaining FDC architecture.
    • BAFF (B-cell Activating Factor): Secreted by FDCs and myeloid cells, binds to the BAFF receptor (BAFF-R) on transitional B cells, providing essential anti-apoptotic survival signals.
  • Successful receipt of these trophic signals completes maturation: cells downregulate surface IgM and upregulate surface IgD, transitioning from an immature transitional B cell ($\text{IgM}^{\text{high}}\text{IgD}^{\text{low}}$) into a mature, naive immunocompetent B cell ($\text{IgM}^{\text{low}}\text{IgD}^{\text{high}}$).

• Antigen Activation and Germinal Center Reactions:

  • When a mature naive B cell binds cognate antigen, it internalizes it, migrates to the boundary between the primary follicle and the T-cell zone, and presents peptides on MHC class II to antigen-primed helper T ($\text{Tfh}$) cells.
  • Following CD40:CD40L and cytokine stimulation, activated B cells follow two developmental paths:
    • Primary Focus: Some migrate to the medullary cords or splenic red pulp to differentiate into low-affinity, short-lived plasma cells secreting early IgM.
    • Germinal Center Formation: Others migrate back into the primary follicle to establish a germinal center, transitioning the follicle into a secondary lymphoid follicle. Within the dark zone, rapidly proliferating B cells (centroblasts) undergo somatic hypermutation (targeted cytidine deamination mediated by Activation-Induced Cytidine Deaminase, or AID) within the $V(D)J$ segments. Centroblasts then exit the cell cycle as centrocytes and enter the light zone to undergo selection: centrocytes whose mutated BCRs bind antigen displayed on FDCs with high affinity capture the antigen, present it to follicular helper T cells, receive CD40L survival signals (affinity maturation), and undergo class-switch recombination.
  • Selected centrocytes differentiate into either high-affinity antibody-secreting plasma cells or quiescent memory B cells.

• Terminally Differentiated B-Cell States:

  • Plasma Cells: Characterized morphologically by an eccentric "spoke-wheel" nucleus, deeply basophilic cytoplasm, and extensive endoplasmic reticulum/Golgi apparatus. Phenotypically $\text{CD138}^+$ and surface $\text{Ig}^-$. Secrete thousands of immunoglobulin molecules per second. Short-lived plasma cells reside in lymphoid tissues and die within days; long-lived plasma cells home to specialized survival niches in the bone marrow, continuously secreting high-affinity protective antibodies for months to decades.
  • Memory B Cells: Long-lived, non-dividing recirculating lymphocytes that express mutated, isotype-switched surface BCRs and possess elevated anti-apoptotic proteins (Bcl-2). Upon antigen re-encounter, memory cells rapidly differentiate into antibody-secreting cells and re-seed germinal centers for further rounds of somatic hypermutation.

• Comparative Biology of B-Cell Subsets:

• B-Cell Malignancies and Chromosomal Translocations:
  • The double-strand DNA cleavage and somatic recombination machineries that generate antibody diversity pose oncogenic risks if misdirected.
  • Burkitt's Lymphoma: A high-grade B-cell malignancy resulting from a reciprocal chromosomal translocation, commonly $\mathbf{t(8;14)(q24;q32)}$, which translocates the c-Myc proto-oncogene from chromosome 8 into juxtaposition with the potent enhancers of the immunoglobulin heavy-chain locus on chromosome 14, driving constitutive Myc transcription and uncontrolled cellular proliferation.

T-Lymphocyte Development and Thymic Selection

• Thymic Anatomy and Microenvironments:
  • The thymus is a primary lymphoid organ situated in the superior mediastinum above the heart. It consists of multiple outer lobules encapsulated by connective tissue trabeculae, structurally divided into:
    • Cortex: Dense meshwork of bone marrow-derived thymocytes packed closely within a stroma of branched cortical thymic epithelial cells (cTECs).
    • Cortico-Medullary Junction: Transition zone through which progenitor cells enter and mature thymocytes exit via blood venules; populated by resident dendritic cells.
    • Medulla: Inner zone containing mature thymocytes, medullary thymic epithelial cells (mTECs), professional dendritic cells, macrophages, and Hassall's corpuscles (concentric whorls of degenerating epithelial cells).

• Thymic Involution:

  • The thymus reaches its maximal absolute physical size and weight ($30\text{--}40\,\text{grams}$) at puberty ($\sim 10\,\text{years}$ of age). Following puberty, the organ undergoes progressive age-related involution, characterized by the replacement of active thymic parenchyma with adipose tissue. Consequently, naive T-cell output falls sharply ($>90\%$ reduction past age 50), with the adult peripheral T-cell compartment maintained primarily by the homeostatic proliferation of mature naive and memory T-cell pools.

• Clinical Correlate — DiGeorge Syndrome:

  • Caused by a congenital microdeletion on chromosome $22\text{q}11.2$, encompassing the TBX1 transcription factor gene, resulting in defective embryological development of the third and fourth pharyngeal pouches.
  • Pathological Features: Congenital absence or hypoplasia of the thymus (causing profound T-cell deficiency, secondary susceptibility to viral and fungal opportunistic infections, and defective cell-mediated immunity), absence of parathyroid glands (producing severe hypocalcemia and tetany), congenital conotruncal cardiac anomalies (Tetralogy of Fallot, interrupted aortic arch), cleft palate, and distinctive facial dysmorphisms.

• T-Cell Lineage Commitment and Notch Signaling:

  • Circulating lymphoid progenitors homing to the thymus lack TCR, CD4, and CD8. Commitment to the T-cell fate requires continuous interaction with thymic stromal cells presenting transmembrane ligands (Delta-like) that engage the receptor Notch1 on thymocytes.
  • Mechanism: Ligand binding triggers proteolytic cleavage of Notch1 by presenilin-dependent $\gamma$-secretase, releasing the Notch1 intracellular domain (NICD). The NICD translocates directly to the nucleus, associates with the DNA-binding factor CSL, displaces co-repressor complexes, and recruits co-activators to drive the transcription of T-cell-specific genes while actively repressing alternative B-cell and myeloid differentiation programs.

• Sequential Stages of Thymocyte Maturation:

  • Double-Negative (DN) Phases: Defined by the absence of CD4 and CD8 expression:
    • DN1 / Early Thymic Progenitor (ETP): $\text{CD44}^+, \text{CD25}^-, \text{c-Kit (CD117)}^{\text{high}}$. Progenitor migration into the cortico-medullary junction.
    • DN2: $\text{CD44}^+, \text{CD25}^+, \text{c-Kit}^{\text{high}}$. Migration into the subcapsular cortex; T-cell lineage commitment; rearrangement at TCR $\beta$, $\gamma$, and $\delta$ loci begins.
    • DN3: $\text{CD44}^-, \text{CD25}^+, \text{c-Kit}^{\text{low}}$. Cellular arrest in the subcapsular cortex; test of functional TCR $\beta$-chain rearrangement ($\beta$-selection).
    • DN4: $\text{CD44}^-, \text{CD25}^-$. Downregulation of CD25 following pre-TCR signaling; entry into rapid proliferation.
  • Intermediate Single Positive (ISP): Transient $\text{CD8}^+ \text{CD4}^-$ stage transitioning into double-positive cells.
  • Double-Positive (DP): $\text{CD4}^+ \text{CD8}^+$. Represents $\sim 80\%$ of thymocytes; halts division; initiates TCR $\alpha$-chain rearrangement; undergoes positive and negative selection in the cortex.
  • Single-Positive (SP): Mature $\text{CD4}^+ \text{CD8}^-$ or $\text{CD4}^- \text{CD8}^+$ thymocytes undergoing negative selection in the medulla before entering the systemic circulation.

• The Lineage Decision: $\alpha:\beta$ vs. $\gamma:\delta$ T Cells:

  • At the DN2–DN3 stage, rearrangements occur at the $\beta$, $\gamma$, and $\delta$ gene loci simultaneously.
  • The Competitive Kinetic Race: If productive in-frame rearrangements occur at both the $\gamma$ and $\delta$ loci prior to a functional $\beta$ rearrangement, a functional $\gamma:\delta$ TCR associates with CD3, signaling cellular commitment to the $\gamma:\delta$ lineage. These cells shut down further rearrangement, leave the thymus, and home directly to peripheral epithelia without undergoing MHC-mediated selection.
  • If a productive TCR $\beta$ rearrangement occurs first, the $\beta$ chain pairs with the invariant surrogate chain $\text{pT}\alpha$ and CD3 to assemble the Pre-T-cell Receptor (Pre-TCR).

• Pre-TCR Assembly and $\beta$-Selection Checkpoint:

  • The pre-TCR forms a superdimer (two $\text{pT}\alpha:\beta$ heterodimers cross-linking each other head-to-tail), which signals constitutively without ligand binding.
  • Functional Consequences of Pre-TCR Signaling:
    1. Halts further rearrangement at the TCR $\beta$ locus through the degradation of RAG-2 and chromatin closure (allelic exclusion).
    2. Drives intense proliferation in the subcapsular cortex, expanding the pool of pre-T cells possessing this validated $\beta$ chain.
    3. Induces expression of both CD4 and CD8 coreceptors (generating DP thymocytes).
    4. Permits re-expression of RAG-1 and RAG-2 to initiate rearrangement at the TCR $\alpha$-chain locus.
  • Rescue Capacity of the $\beta$ Locus: Due to the two tandem $D_{\beta 1}\text{--}J_{\beta 1}\text{--}C_{\beta 1}$ and $D_{\beta 2}\text{--}J_{\beta 2}\text{--}C_{\beta 2}$ cassettes on each chromosome, thymocytes can make up to four successive attempts to productively rearrange a $\beta$ chain ($2\,\text{per chromosome}$), achieving an overall success rate of $\sim 80\%$.

• TCR $\alpha$-Chain Rearrangement and Deletion of the $\delta$ Locus:

  • Unlike the $\beta$ chain, the $\alpha$-chain locus contains no $D$ segments and does not enforce allelic exclusion during early selection. Pre-T cells can perform repeated, successive $V_\alpha\text{--}J_\alpha$ rearrangements on both alleles until an $\alpha$ chain is produced that successfully mediates positive selection.
  • *Obligate Deletion of TCR \delta$:* Because the entire TCR \delta$gene locus is situated geographically between the$V_\alpha$and$J_\alpha$segments on chromosome 14, **any rearrangement at the$\alpha$locus invariably excises the$\delta$locus** as an extrachromosomal circular DNA product, permanently extinguishing the cell's ability to become a$\gamma:\delta T cell.\n\n\n# Thymic Selection and the Induction of Central and Peripheral Tolerance\n\n* **Positive Selection (Cortical MHC Restriction):**\n * Takes place in the thymic cortex, mediated by cortical thymic epithelial cells (**cTECs**) presenting self-peptides in the grooves of surface MHC class I and class II molecules.\n * *The Affinity Hypothesis / Selection Outcomes:*\n * **Death by Neglect (>90\text{--}95\%$of DP thymocytes):** TCRs that exhibit weak or no affinity for self-peptide:MHC complexes fail to receive tonic survival signals and undergo apoptosis within$3\text{--}4\,\text{days}.\n * **Positive Selection (2\text{--}5\% of DP thymocytes):** TCRs that bind with low-to-moderate affinity to self-peptide:MHC complexes receive anti-apoptotic survival signals and are signaled to mature.\n * *Lineage Commitment:* Co-receptor engagement during positive selection determines single-positive divergence:\n * If the DP thymocyte's TCR binds to **MHC class I**, CD8-associated Lck signals sustained survival, CD4 transcription is permanently silenced, and the cell becomes a mature **\text{CD8}^+ Single-Positive CTL**.\n * If the TCR binds to **MHC class II**, CD4 signaling silences CD8 expression, yielding a mature **\text{CD4}^+ Single-Positive Helper T Cell**.\n\n\n\n* **Negative Selection (Medullary Clonal Deletion):**\n * Takes place at the cortico-medullary junction and within the medulla, mediated primarily by **mTECs**, resident medullary dendritic cells, and macrophages.\n * *Clonal Deletion:* Developing thymocytes whose TCRs bind to self-peptide:MHC complexes with **high affinity** receive strong apoptotic signals, purging potentially self-reactive clones to prevent autoimmunity.\n\n* **The AIRE Transcription Factor and Central Tolerance:**\n * Effective negative selection requires displaying self-antigens that are normally expressed only in distant peripheral organs (e.g., insulin in pancreatic \beta-islets, thyroglobulin in the thyroid, retinal proteins in the eye).\n * **Autoimmune Regulator (AIRE):** A master transcriptional regulator expressed in mTECs that directs chromatin decondensation, permitting the "promiscuous" or ectopic expression of thousands of peripheral tissue-restricted antigens (TRAs) within the thymic medulla.\n * *Clinical Syndrome — APECED (APS-1):* Mutations in the *AIRE* gene cause Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (also known as Autoimmune Polyglandular Syndrome Type 1), an autosomal recessive disease with an incidence of 1:100{,}000.\n * *Diagnostic Triad:* Chronic mucocutaneous candidiasis (due to failure of T-cell immunity and autoantibodies against IL-17), hypoparathyroidism (autoimmune destruction of parathyroids causing hypocalcemia, tetany, muscle cramping, and digital paresthesias), and adrenal insufficiency (Addison's disease causing orthostatic hypotension, weakness, fatigue, hyperpigmentation, and hypoglycemia).\n\n* **Regulatory T Cells (Tregs) and Peripheral Tolerance Mechanisms:**\n * *Natural Treg Generation:* A subset of \text{CD4}^+$thymocytes whose TCRs exhibit intermediate-to-high affinity for self-peptide:MHC class II complexes—bordering on the threshold of negative selection—escape deletion and differentiate into **regulatory T cells (Tregs)**, characterized by constitutive expression of **CD25** (IL-2R$\alpha chain) and the master lineage forkhead transcription factor **FoxP3**.\n * *Mechanisms of Extrathymic Suppression:* Autoreactive effector T cells that escape thymic negative selection enter the periphery, where they are restrained by:\n * **Anatomical Sequestration:** Spatial isolation behind blood-tissue barriers (central nervous system, eye, testes).\n * **Anergy:** Engagement of TCR without co-stimulatory B7 signaling renders self-reactive T cells functionally unresponsive.\n * **Active Treg Suppression:** Tregs home to the same antigen-presenting cells as autoreactive effector cells, suppressing them via contact-dependent CTLA-4-mediated stripping of B7 molecules, local depletion of IL-2 via high-affinity CD25 capture, and secretion of immunosuppressive cytokines (IL-10, TGF-\beta, and IL-35).\n\n\n# Dendritic Cell Maturation and Naive T-Cell Activation in Secondary Lymphoid Organs\n\n* **Functional Phenotypes of Dendritic Cells:**\n * **Immature DCs (Peripheral Tissues):** Highly endocytic and phagocytic cells expressing high levels of Pattern Recognition Receptors (TLRs, C-type lectins). Express low surface MHC class I and class II, low co-stimulatory B7, and maintain an intracellular reservoir of MHC class II within late endosomes.\n * **Mature / Activated DCs (Lymphoid Tissues):** Upon pathogen recognition and inflammatory cytokine exposure (TNF-\alpha, IL-1), DCs downregulate phagocytic capacity and remodel their surface phenotype:\n * Upregulate the chemokine receptor **CCR7**, directing migration out of tissues into afferent lymphatic vessels toward the gradient of **CCL21** and **CCL19** produced in draining lymph nodes.\n * Massively upregulate surface stability and expression of peptide-loaded MHC class I and MHC class II complexes.\n * Upregulate co-stimulatory molecules (**CD80/B7-1** and **CD86/B7-2**) and adhesion ligands (**ICAM-1**).\n * Morphologically convert into interdigitating dendritic cells with elongated dendrites, establishing expansive surface area within the paracortex (T-cell area) of draining lymph nodes to screen thousands of recirculating naive T cells.\n\n* **Naive T-Cell Extravasation into Lymph Nodes:**\n * Naive T cells home from the bloodstream across **High Endothelial Venules (HEVs)** into the lymph node paracortex via a coordinated four-step extravasation cascade:\n 1. *Rolling:* **L-selectin (CD62L)** on naive T cells binds to sulfated sialyl-Lewis\(^X\) carbohydrate moieties on vascular addressins (**GlyCAM-1** and **CD34**) decorating the HEV luminal surface.\n 2. *Activation:* Chemokines **CCL21** and **CCL19** displayed on the HEV lumen engage **CCR7** on the rolling T cell, triggering G-protein-coupled "inside-out signaling."\n 3. *Firm Adhesion:* Inside-out signals induce an active, extended high-affinity conformation in the integrin **LFA-1** (\alpha_L\beta_2$$), which binds tightly to ICAM-1 on the endothelial cell.
    4. Diapedesis: The firmly adherent T cell transmigrates between endothelial cell junctions across the vessel basement membrane into the T-cell paracortex.

• The Immunological Synapse and Conjugate Formation:

  • Initial encounter between a naive T cell and a mature DC is mediated by low-affinity adhesion between T-cell LFA-1 and DC ICAM-1, allowing transient scanning of presented peptide:MHC complexes.
  • Specific engagement of the TCR by a cognate peptide:MHC complex generates signaling that feeds back to LFA-1, stabilizing its high-affinity conformation and prolonging physical contact for hours.
  • Membrane molecules and the actin/microtubule cytoskeleton rapidly reorganize and polarize toward the site of contact, forming the immunological synapse:
    • c-SMAC (Central Supramolecular Activation Cluster): Concentrates TCR, CD4 or CD8 co-receptors, CD28, and signaling kinases (Lck, ZAP-70).
    • p-SMAC (Peripheral Supramolecular Activation Cluster): Forms a surrounding adhesive ring dominated by LFA-1:ICAM-1 complexes and talin, anchoring the conjugate.
    • d-SMAC (Distal Supramolecular Activation Cluster): Outer ring containing bulky, negatively charged molecules with large ectodomains (such as CD43 and CD45) that are excluded from the central signaling hub.